Careers at Pfizer
Pfizer aims to develop and sell a range of effective prescription medicines, over-the-counter medications and healthcare products for customers worldwide.
Pfizer’s commercial operations are divided into two distinct business: Innovative Products business and an Established Products, the former of which is further divided into two segments. As such, Pfizer’s operations are organised into three operating segments:
- Global Innovative Pharmaceutical segment, which comprises the Company’s development and commercialisation of novel and innovative medicines designed to improve patients’ lives;
- Global Vaccines, Oncology and Consumer Healthcare segment, which comprises the Company’s development and commercialisation of vaccines and products for oncology and consumer healthcare; and
- Global Established Pharmaceutical segment, comprising the Company’s development and commercialisation of legacy brands that have lost or will soon lose market exclusivity, branded generics, generic sterile injectable products, biosimilars and infusion systems.
Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849. The Company had some early success with an antiparisitic named Santonin, but experienced significant growth following its move into the production of citric acid in the 1880s. It focused on the production of citric acid through most of the first half of the 20th Century, despite some difficulties caused by the First and Second World Wars.
Once penicillin became more readily available, Pfizer began developing and commercialising new antibiotic products, ultimately changing the Company’s focus from a manufacturer of fine chemicals to an outright pharmaceutical company. Pfizer continued to develop its product portfolio and expanded its interests internationally, establishing offices across Europe, North America, and Latin America by the 1950s.
Pfizer has continued to expand and grow, and is today not only one of the largest pharmaceutical groups in the world but one of the largest companies in any sector, with an international network of offices and research facilities, and close to 100,000 employees. The Company is ranked 55th in the Fortune 500 List. Pfizer’s shares are traded on the New York Stock Exchange. It has a current market capitalisation of $212.18 billion.
Business model of Pfizer
Pfizer sells its products to a range of customers active within the healthcare and medical sector. The Company’s prescription pharmaceutical products and consumer health products are sold principally to wholesalers and distributors, as well as to retailers, hospitals, clinics, government agencies and pharmacies. Pfizer also sells its vaccines products in the US directly to individual provider offices, the Centre for Disease Control and Prevention and wholesalers.
In 2015, Pfizer’s top three biopharmaceutical wholesaler customers – McKesson, AmerisourceBergen and Cardinal Health – accounted for approximately 34% of the Company’s total revenues, and around 74% of its total US revenues.
Pfizer serves customers across four geographic segments: the US, Developed Europe, Developed Rest of the World, and Emerging Markets. The US remains the Company’s most significant market, which accounts for almost half the Company’s total revenue.
Pfizer provides value to its customers in the following ways:
- Its brand reputation and industry standing, with the Company being one of the largest and most well-established pharmaceutical groups in the world, with a track-records for providing quality products;
- Its broad portfolio of products, with the Company delivering medications and products that target a broad spectrum of customers and cover a range of ailments and conditions;
- Its international sales and marketing reach, with the Company serving customers across developed markets including in Europe, North America and Asia, as well as emerging markets across Latin America, Africa and the Middle East; and
- Its commitment to innovation, with the Company devoting a substantial portion of its revenue to research and development activities, with a view to providing new and unique products.
Pfizer operates a website at www.pfizer.com, through which it provides information to customers on its various products, services and business activities. The Company also operates regional websites in various languages for its international customers. Pfizer does not operate an online sales channel.
Pfizer makes the majority of its sales through its own in-house sales and marketing organisations. The Company’s sales and marketing teams are organised by segment and by geographic region, with Pfizer maintaining a sales presence across countries in Europe, North America, Asia Pacific, Latin America, and Africa. The Company’s consumer products are also sold through pharmacies, retail chains and grocery and convenience stores.
Pfizer’s direct sales force is supported by a network of channel partners, primarily distributors, in smaller markets where it does not have a significant presence.
While Pfizer does maintain an online presence, the Company does not make its products available online on a self-service. Consumers are able to purchase products on a self-service basis from retail chains and pharmacies, but not directly from Pfizer.
Pfizer’s customers must interact directly with the Company’s sales teams, typically agreeing long-term, multi-year contracts. Consulting directly with customers enables Pfizer to provide a bespoke service that covers the specific needs of each individual client.
Pfizer provides worldwide contact information, enabling customers to get in touch with the relevant company department in the correct jurisdiction in order to get real-time assistance from Pfizer representatives. This includes email and telephone support. The Company also provides online information and FAQs through its website.
Customers can also interact directly with Pfizer through its social media accounts, including with YouTube, Facebook, Twitter, Sina Weibo, LinkedIn and SlideShare.
Pfizer is a research-based multinational biopharmaceutical group. The Company is engaged in the developing, production and sale of prescription and over-the-counter medications and healthcare products. Pfizer’s product portfolio spans medicines, vaccines and medical devices, as well as consumer healthcare products.
The Company’s commercial operations comprise two businesses: Innovative Products business and Established Products business. The Innovative Products business is further segregated into of two segments: the Global Innovative Pharmaceutical segment – which covers the development of new medications and treatments – and the Global Vaccines, Oncology and Consumer Healthcare segment, which focuses on consumer health and cancer treatment. Pfizer’s research activities focus on six areas, including immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases.
Pfizer partners with a range of international partners throughout the development, production and sale of its products. These partners can broadly be categorised as follows:
- Research and Development Partners, comprising academic and healthcare institutions which assist in the development of the Company’s various products by providing expertise, resources and technology;
- Manufacturing and Supply Chain Partners, comprising manufacturing and pharmaceutical companies that assist the Company in producing its products by providing supplies, facilities and expertise;
- Channel Partners, comprising distributers and independent sales agents that extend the Company’s own in-house sales and marketing reach;
- Strategic and Alliance Partners, comprising pharmaceutical and technology companies with which the Company collaborates on joint venture projects and shares resources; and
- Corporate Responsibility Partners, comprising non-profits, non-governmental organisations and public bodies with which the Company cooperates on social projects.
Pfizer includes Parexel, Icon, PPD, Merck, IndieGoGo, Rexall and NovaMedica among its partners.
Pfizer’s key resources are its technologies and intellectual properties, its research and development facilities, its manufacturing and supply chain networks, its sales and distribution channels, and its personnel.
Pfizer uses a range of patents and trademarks to protect its intellectual properties, which it considers to be material to its ongoing business activities.
Searches of records published by the US Patent and Trademark Office identified a number of patent applications filed in Pfizer’s name, including applications entitled ‘Diacylglycerol acyltransferase 2 inhibitors’, ‘Substituted amide compounds’ and ‘Cytotoxic peptides and antibody drug conjugates thereof’.
Pfizer incurs costs in relation to the development of its products, the management of its supply chain, the production of its products, the sale and marketing of its products, the management of its partnerships, and the retention of its personnel.
Pfizer accrues substantial research and development costs. In 2015 these expenses to $7.7 billion, compared to $8.4 billion in 2014. The Company also accrues significant general and administrative costs, comprising the payment of salaries and benefits to its international workforce of around 98,000 and the payment of rental and utility fees for its network of international offices and facilities.
Pfizer generates revenue through the development and sale of pharmaceutical products – including prescription medicines, over-the-counter medications, consumer healthcare products and specialist oncology solutions. The Company also derives a small amount of revenue from various alliance agreements, under which it co-promotes products created by third-party companies.
In 2015, Pfizer generated $48.85 billion in total annual revenue, down slightly on the $49.61 billion recorded by the Company in 2014. The Company’s Global Established Pharmaceutical segment is its largest revenue generator, accounting in 2015 for $21.59 billion in revenue. Pfizer’s Global Innovative Pharmaceutical segment and Global Vaccines, Oncology and Consumer Healthcare segment generated $13.95 billion and $12.80 billion respectively.
info: Ian Read (“Read”) has served as Pfizer’s Chairman and Chief Executive Officer since 2010. Read also serves on the boards of PhRMA, Kimberly-Clark, and the Partnership for New York City. Prior to his appointment as Chief Executive Officer, Read served as President of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. He began his career with Pfizer in 1978, joining the Company as an operational auditor. He worked in Latin America until 1995, serving in roles including Chief Financial Officer of Pfizer Mexico, and Country Manager of Pfizer Brazil. Read was appointed President of Pfizer’s International Pharmaceuticals Group in 1996, and was named Executive Vice President for Europe in 2000. Read went on t0 serve as Corporate Vice President from 2001, assumed responsibility for operations in Canada and Europe in 2002, and later headed up operations across Africa, the Middle East and Latin America. Read holds a bachelor’s degree in Chemical Engineering from London University Imperial College, and a Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales.
info: Frank D’Amelio (“D’Amelio”) has served as Executive Vice President for Business Operations and Chief Financial Officer at Pfizer since 2007. He also serves as a director of Humana, and as chair of the Audit Committee at Zoetis, the Independent College Fund of New Jersey, and the Gillen-Brewer School. D’Amelio began his career at Bell Labs, before moving to AT&T. He joined Lucent when it was spun off from AT&T in 1996, serving as the Chief Financial Officer of Lucent’s Network Systems Business. A year later he was appointed Group President of Lucent’s Switching Solutions Group, where he led company’s global Switching, Access and Application Software businesses. D’Amelio went on to serve as Executive Vice President and Chief Financial Officer at Lucent from 2001, and later as Chief Operating Officer until the company’s merger with Alcatel in 2007. His last role before joining Pfizer was as Senior Executive Vice President of Integration and Chief Administrative Officer at the newly-merged Alcatel-Lucent. D’Amelio holds a master’s degree in Business Administration from St. John’s University and a bachelor’s degree in Accounting from St. Peter’s College.
info: Rod MacKenzie (“MacKenzie”) has served as Pfizer’s Executive Vice President and Chief Development Officer since 2016. MacKenzie represents Pfizer on the board for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer. MacKenzie has been with Pfizer since 1986, joining the Company as a research scientist. He has since gone on to hold senior leadership positions within the Company, including spells as Head of PharmaTherapeutics Research and Development, Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global research and development facility. Prior to this role, Rod held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, UK, Head of the Discovery Technology Centre in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety Research and Development.
Jobs at Pfizer
1.730.000+ job opportunitiesStart here!